RobertMDS Patient

The Right Expression Can Change a Life

When genes are expressed - turned on, off, up or down - at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By creating medicines to control the expression of genes, we aim to make a profound difference in the lives of patients and their families. We are advancing a growing pipeline of investigational gene control medicines for diseases that have largely eluded other genomics-based approaches. Our current focus is on cancer, including immuno-oncology, and genetic diseases.

Program Indication Discovery Preclinical Early Clinical Mid-Stage Clinical Pivotal Commercial Rights
SY-1425 (RARα agonist)
SY-1425 (RARα agonist)
Frontline AML (combination with azacitidine)
Discovery Phase complete
Preclinical Phase complete
Early Clinical Phase complete
Mid-Stage Clinical Phase in progress
Pivotal Phase not started
Syros (North America & Europe)
Syros (North America & Europe)
SY-1425 (RARα agonist)
R/R AML and HR MDS (combination with daratumumab)
Discovery Phase complete
Preclinical Phase complete
Early Clinical Phase complete
Mid-Stage Clinical Phase in progress
Pivotal Phase not started
Syros (North America & Europe)
SY-1365 (CDK7 inhibitor)
SY-1365 (CDK7 inhibitor)
Relapsed ovarian cancer, 3+ prior lines (single agent)
Discovery Phase complete
Preclinical Phase complete
Early Clinical Phase in progress
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
SY-1365 (CDK7 inhibitor)
Relapsed ovarian cancer, 1+ prior lines (combination with carboplatin)
Discovery Phase complete
Preclinical Phase complete
Early Clinical Phase in progress
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
SY-1365 (CDK7 inhibitor)
Primary platinum-refractory ovarian cancer (single agent)
Discovery Phase complete
Preclinical Phase complete
Early Clinical Phase in progress
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
SY-1365 (CDK7 inhibitor)
HR+ metastatic breast cancer (combination with fulvestrant)
Discovery Phase complete
Preclinical Phase complete
Early Clinical Phase in progress
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
SY-5609 (Oral CDK7 inhibitor)
SY-5609 (Oral CDK7 inhibitor)
Cancer
Discovery Phase complete
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
CDK12/13 Inhibitor
CDK12/13 Inhibitor
Cancer
Discovery Phase complete
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
Program 5
Program 5
Immuno-oncology
Discovery Phase complete
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
Discovery
Discovery
Cancer/Immuno-oncology
Discovery Phase in progress
Preclinical Phase not started
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)
Discovery
Sickle Cell Disease  
Discovery Phase in progress
Preclinical Phase not started
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Discovery
Discovery
Myeloproliferative neoplasms
Discovery Phase in progress
Preclinical Phase not started
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Incyte (Global)
Incyte (Global)

Interested in Participating in a Clinical Trial?

If you’re interested in participating in a clinical trial, check to see if a trial is open near your area and if you meet the requirements to participate.

Learn More

Partnership Opportunities

We seek partnerships that maximize value for us and our partners by extending the potential of our gene control platform across multiple therapeutic areas and diseases.

View Our Partnership Focus

Our Publications and Abstracts

Learn more about the science and data behind our platform and our programs.

Read Publications and Abstracts